Innoviva Current Ratio 2010-2024 | INVA
Innoviva current ratio from 2010 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Innoviva Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2024-09-30 |
$0.40B |
$0.22B |
1.79 |
| 2024-06-30 |
$0.36B |
$0.03B |
12.70 |
| 2024-03-31 |
$0.31B |
$0.03B |
10.42 |
| 2023-12-31 |
$0.34B |
$0.04B |
9.03 |
| 2023-09-30 |
$0.31B |
$0.04B |
8.43 |
| 2023-06-30 |
$0.32B |
$0.04B |
8.21 |
| 2023-03-31 |
$0.30B |
$0.04B |
7.77 |
| 2022-12-31 |
$0.44B |
$0.14B |
3.29 |
| 2022-09-30 |
$0.46B |
$0.16B |
2.77 |
| 2022-06-30 |
$0.40B |
$0.13B |
3.18 |
| 2022-03-31 |
$0.32B |
$0.11B |
2.91 |
| 2021-12-31 |
$0.31B |
$0.01B |
54.02 |
| 2021-09-30 |
$0.24B |
$0.00B |
75.82 |
| 2021-06-30 |
$0.15B |
$0.01B |
27.60 |
| 2021-03-31 |
$0.37B |
$0.00B |
98.04 |
| 2020-12-31 |
$0.34B |
$0.01B |
55.98 |
| 2020-09-30 |
$0.57B |
$0.00B |
146.75 |
| 2020-06-30 |
$0.50B |
$0.01B |
92.39 |
| 2020-03-31 |
$0.47B |
$0.00B |
166.87 |
| 2019-12-31 |
$0.43B |
$0.01B |
80.29 |
| 2019-09-30 |
$0.37B |
$0.00B |
110.18 |
| 2019-06-30 |
$0.32B |
$0.01B |
42.50 |
| 2019-03-31 |
$0.25B |
$0.00B |
66.02 |
| 2018-12-31 |
$0.20B |
$0.01B |
34.92 |
| 2018-09-30 |
$0.12B |
$0.00B |
28.18 |
| 2018-06-30 |
$0.18B |
$0.01B |
26.36 |
| 2018-03-31 |
$0.11B |
$0.00B |
27.85 |
| 2017-12-31 |
$0.20B |
$0.04B |
5.77 |
| 2017-09-30 |
$0.22B |
$0.03B |
6.71 |
| 2017-06-30 |
$0.20B |
$0.03B |
7.31 |
| 2017-03-31 |
$0.21B |
$0.02B |
10.47 |
| 2016-12-31 |
$0.20B |
$0.02B |
9.88 |
| 2016-09-30 |
$0.19B |
$0.02B |
12.47 |
| 2016-06-30 |
$0.19B |
$0.02B |
13.02 |
| 2016-03-31 |
$0.20B |
$0.01B |
18.52 |
| 2015-12-31 |
$0.21B |
$0.01B |
15.89 |
| 2015-09-30 |
$0.22B |
$0.01B |
19.84 |
| 2015-06-30 |
$0.24B |
$0.01B |
19.97 |
| 2015-03-31 |
$0.26B |
$0.01B |
23.90 |
| 2014-12-31 |
$0.25B |
$0.01B |
18.33 |
| 2014-09-30 |
$0.27B |
$0.04B |
7.58 |
| 2014-06-30 |
$0.35B |
$0.05B |
7.06 |
| 2014-03-31 |
$0.39B |
$0.04B |
8.82 |
| 2013-12-31 |
$0.48B |
$0.08B |
5.73 |
| 2013-09-30 |
$0.52B |
$0.04B |
13.51 |
| 2013-06-30 |
$0.46B |
$0.04B |
11.83 |
| 2013-03-31 |
$0.48B |
$0.03B |
16.11 |
| 2012-12-31 |
$0.26B |
$0.03B |
8.71 |
| 2012-09-30 |
$0.28B |
$0.03B |
10.43 |
| 2012-06-30 |
$0.30B |
$0.03B |
11.77 |
| 2012-03-31 |
$0.20B |
$0.03B |
7.99 |
| 2011-12-31 |
$0.25B |
$0.05B |
5.38 |
| 2011-09-30 |
$0.27B |
$0.04B |
6.76 |
| 2011-06-30 |
$0.29B |
$0.04B |
8.20 |
| 2011-03-31 |
$0.30B |
$0.03B |
8.99 |
| 2010-12-31 |
$0.32B |
$0.04B |
7.90 |
| 2010-09-30 |
$0.20B |
$0.04B |
5.43 |
| 2010-06-30 |
$0.22B |
$0.04B |
6.01 |
| 2010-03-31 |
$0.23B |
$0.04B |
6.53 |
| 2009-12-31 |
$0.16B |
$0.04B |
4.16 |
| 2009-09-30 |
$0.16B |
$0.04B |
4.14 |
| 2009-06-30 |
$0.18B |
$0.04B |
4.57 |
| 2009-03-31 |
$0.19B |
$0.04B |
5.08 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.122B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
